Eucalyptol

Nurtec ODT ( rimegepant ) is a prescription medicine used to treat acute migraine attacks with or without aura and for the preventive treatment of episodic migraine in adults. It is an orally disintegrating tablet (ODT) that dissolves on or under the tongue and can be taken without water. In clinical trials, 59.3% of Nurtec patients had pain relief within 2 hours of taking it for acute migraine pain, and 21.2% were pain-free at 2 hours (Study 1). Nurtec is taken when required for acute migraine treatment, up to a maximum of 1 tablet in 24 hours. For preventing migraines, one Nurtec tablet is taken every other day. The safety of using more than 18 doses in 30 days has not been established. Nurtec works by blocking the action of calcitonin gene-related peptide (CGRP), a protein involved in migraine attacks. CGRP is thought to contribute to migraine pain, inflammation, and widening of blood vessels in the brain. By blocking CGRP receptors, Nurtec may help relieve migraine symptoms and help prevent future migraine attacks. It belongs to a class of medicines called CGRP receptor antagonists (gepants). The U.S. Food and Drug Administration (FDA) first approved Nurtec ODT on February 27, 2020. There is no generic available.

Nurtec ODT ( rimegepant ) is a prescription medicine used to treat acute migraine attacks with or without aura and for the preventive treatment of episodic migraine in adults. It is an orally disintegrating tablet (ODT) that dissolves on or under the tongue and can be taken without water. In clinical trials, 59.3% of Nurtec patients had pain relief within 2 hours of taking it for acute migraine pain, and 21.2% were pain-free at 2 hours (Study 1). Nurtec is taken when required for acute migraine treatment, up to a maximum of 1 tablet in 24 hours. For preventing migraines, one Nurtec tablet is taken every other day. The safety of using more than 18 doses in 30 days has not been established. Nurtec works by blocking the action of calcitonin gene-related peptide (CGRP), a protein involved in migraine attacks. CGRP is thought to contribute to migraine pain, inflammation, and widening of blood vessels in the brain. By blocking CGRP receptors, Nurtec may help relieve migraine symptoms and help prevent future migraine attacks. It belongs to a class of medicines called CGRP receptor antagonists (gepants). The U.S. Food and Drug Administration (FDA) first approved Nurtec ODT on February 27, 2020. There is no generic available.

Before taking Nurtec ODT, tell your healthcare provider about all of your medical conditions, especially if you: have high blood pressure have circulation problems in your fingers or toes have liver problems have kidney problems are pregnant or plan to become pregnant are breastfeeding or plan to breastfeed A pregnancy exposure registry called MONITOR is available for women who take Nurtec ODT during pregnancy. Very small amounts of Nurtec ODT pass into breast milk, so ask your healthcare provider about the best way to feed your baby while taking this medicine. Do not use this medicine if you have a history of an allergy to rimegepant or any of the inactive ingredients in this medicine. Tell your healthcare provider about all medicines you take, including prescription drugs, over-the-counter medicines, vitamins, and herbal supplements.

The severe or irreversible adverse effects of Eucalyptol, which give rise to further complications include Aspiration Secondary to vomiting and loss of consciousness, Weak Carcinogenic activity on mouse skin. The symptomatic adverse reactions produced by Eucalyptol are more or less tolerable and if they become severe, they can be treated symptomatically, these include Vomiting, Aspiration, Unconsciousness, Burning Sensation after Injection.

Nurtec may cause serious side effects and should be used with caution in some patients. Allergies (hypersensitivity reactions): Nurtec can cause serious allergic reactions, including anaphylaxis, shortness of breath, and rash. These reactions can happen days after administration. If a hypersensitivity reaction occurs, stop taking this medicine and seek appropriate medical treatment. Low blood pressure (hypertension): This medicine may cause new-onset high blood pressure or worsening of pre-existing hypertension. Postmarketing cases have included patients who required blood pressure medicine and, in some cases, hospitalization. High blood pressure may occur at any time during treatment, but it has been reported most often within 7 days of starting therapy. Raynaud’s phenomenon: This medicine may cause new-onset Raynaud’s phenomenon or worsen pre-existing Raynaud’s phenomenon. In reported cases with small-molecule CGRP antagonists, symptoms began a median of 1.5 days after dosing. If signs or symptoms of Raynaud’s phenomenon develop, Nurtec ODT should be discontinued, and the patient should be evaluated if symptoms do not resolve. Severe hepatic impairment: Avoid use of Nurtec in patients with severe hepatic (liver) impairment (Child-Pugh C) End-stage renal disease (end-stage kidney disease): Nurtec should be avoided in patients with end-stage renal disease (CLcr < 15 mL/min)

Nurtec may cause serious side effects and should be used with caution in some patients. Allergies (hypersensitivity reactions): Nurtec can cause serious allergic reactions, including anaphylaxis, shortness of breath, and rash. These reactions can happen days after administration. If a hypersensitivity reaction occurs, stop taking this medicine and seek appropriate medical treatment. Low blood pressure (hypertension): This medicine may cause new-onset high blood pressure or worsening of pre-existing hypertension. Postmarketing cases have included patients who required blood pressure medicine and, in some cases, hospitalization. High blood pressure may occur at any time during treatment, but it has been reported most often within 7 days of starting therapy. Raynaud’s phenomenon: This medicine may cause new-onset Raynaud’s phenomenon or worsen pre-existing Raynaud’s phenomenon. In reported cases with small-molecule CGRP antagonists, symptoms began a median of 1.5 days after dosing. If signs or symptoms of Raynaud’s phenomenon develop, Nurtec ODT should be discontinued, and the patient should be evaluated if symptoms do not resolve. Severe hepatic impairment: Avoid use of Nurtec in patients with severe hepatic (liver) impairment (Child-Pugh C) End-stage renal disease (end-stage kidney disease): Nurtec should be avoided in patients with end-stage renal disease (CLcr < 15 mL/min)

Scraped Dose — Nurtec ODT is an orally disintegrating tablet. Keep the tablet in the blister pack until you are ready to take it. When taking Nurtec: Use dry hands when opening the blister pack Peel back the foil and gently remove the tablet Do not push the tablet through the foil Place the tablet on or under your tongue right away Allow the tablet to dissolve in saliva Swallow without water Take Nurtec immediately after opening the blister pack. Do not store it outside the packaging for later use. Take this medicine exactly as prescribed by your doctor. Follow all directions on your prescription label and read all medication guides or instruction sheets. Call your doctor if your headaches do not get better or occur more frequently after taking this medicine

No child dosage information is recorded for this medicine yet.

No neonatal dosage information is recorded for this medicine yet.

Sometimes other prescription medicines, nonprescription medicines, vitamins, nutritional supplements, and herbal products that you are taking or plan to take can interact with Nurtec  It is important to tell your doctor about any other products you are taking or when you start or stop taking them. Important drug interactions can happen between Nurtec ODT and the following medicines, so if you are taking any of these, you should tell your doctor, pharmacist, or healthcare professional: Antifungals: Specifically, fluconazole, itraconazole, ketoconazole, and voriconazole; Human immunodeficiency virus (HIV) medications : Specifically, indinavir, nelfinavir, ritonavir, saquinavir, and tipranavir ( Antibiotics: Specifically, clarithromycin, ciprofloxacin, cyclosporine, erythromycin (E.E.S., Eryc, Eryped, Ery-tab), and rifampin. Other Medications: Specifically, aprepitant, conivaptan, crizotinib, diltiazem, dronedarone, fluvoxamine, imatinib, and verapamil. Nurtec is known to have drug interactions with Strong or Moderate CYP3A4 Inhibitors , Strong or Moderate CYP3A Inducers. Nurtec is known to have drug interactions with potent inhibitors of P-gp (e.g., amiodarone, cyclosporine, lapatinib, quinidine, ranolazine) may result in increased exposure of rimegepant. Avoid another dose of Nurtec ODT within 48 hours when it is concomitantly administered with potent inhibitors of P-gp. Your doctor may need to change the doses of your medications, how often or if you should take Nurtec or monitor you carefully for side effects. Many other medications may also interact with Nurtec, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.

Nasal spray, Oint Store in a well closed container. Protect from Sunlight.